GSK Plc ADR(GSK) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 10 at 5:22 PM ET (Korea 9/11 06:22)
Full metrics table
| Index | - | P/E | 15.16 | EPS (ttm) | 3.17 | Insider Own | 0.01% | Shs Outstand | 2.02B | Perf Week | -4.6% |
| Market Cap | 96.41B | Forward P/E | 9.4 | EPS next Y | 6.92% | Insider Trans | - | Shs Float | 2.00B | Perf Month | -5.46% |
| Enterprise Value | 115.87B | PEG | 1.99 | EPS next Q | 1.37 | Inst Own | 17.42% | Short Float | 0.74% | Perf Quarter | -5.96% |
| Income | 6.48B | P/S | 2.16 | EPS this Y | 1.87% | Inst Trans | -2.67% | Short Ratio | 3.95 | Perf Half Y | -12.75% |
| Sales | 44.55B | P/B | 4.16 | EPS next 5Y | 4.73% | ROA | 7.95% | Short Interest | 14.78M | Perf YTD | -1.88% |
| Book/sh | 11.58 | P/C | 23.39 | EPS past 3/5Y | -25.93% 0.08% | ROE | 29.69% | 52W High | -22% ($61.69) | Perf Year | 18.81% |
| Cash/sh | 2.06 | P/FCF | 11.05 | Sales past 3/5Y | 6.03% -0.31% | ROIC | 15.47% | 52W Low | 22.47% ($39.29) | Perf 3Y | 31.66% |
| Dividend Est. | $1.87 (3.89%) | EV/EBITDA | 8.21 | EPS Y/Y TTM | 48.32% | Gross Margin | 73.29% | Volatility(W/M) | 1.62% 1.62% | Perf 5Y | 18.92% |
| Dividend TTM | 1.82 | EV/Sales | 2.6 | Sales Y/Y TTM | 8.82% | Oper. Margin | 25% | ATR (14) | 1.05 | Perf 10Y | 11.22% |
| Dividend Ex-Date | 2026/8/14 | Quick Ratio | 0.52 | EPS Q/Q | -69.33% | Profit Margin | 14.56% | RSI (14) | 35.39 | Recom | 2.57 |
| Dividend Gr. 3/5Y | 8.77% -7.68% | Current Ratio | 0.82 | Sales Q/Q | 5.87% | SMA20 | -4.94% ($50.62) | Beta | 0.34 | Target Price | $58 |
| Payout | 46.93% | Debt/Eq | 1.03 | Earnings | 2026/7/28 | SMA50 | -6.4% ($51.41) | Rel Volume | 0.57 | Prev Close | $48.63 |
| Employees | 66841 | LT Debt/Eq | 0.79 | EPS/Sales Surpr. | 8.28% 1.42% | SMA200 | -8.01% ($52.31) | Avg Volume(3M) | 3.74M | Price | $48.12 |
| IPO | 1980/3/28 | Option/Short | Yes/Yes | Trades | 14269 | Volume | 2,143,336 | Change | -1.05% |
Company
GSK is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💉 A global pharmaceutical company that provides vaccines and specialty medicines (in HIV, respiratory, immunology, oncology, and general pharmaceuticals). It was formed through the merger of Glaxo Wellcome and SmithKline Beecham in 2000 and is headquartered in the UK. It has established itself as a leading player in the global vaccines market.
Over the past 1 year, roughly in the middle
22% below its 1-year high.
GSK has weak earning power
High debt load may weigh on results in a downturn
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +1.9% this year.
Tap to view numbers
The price looks about right
Trading at 15.2 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Long-term returns are close to the market
Would have changed by +31.7% if bought 5 years ago.
Tap to view numbers
Dividends are paid consistently
Pays 3.89% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 17.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
GSKH 0.97%
PPH 0.04%
KEAT 0.04%
DIVY 0.04%
IDVZ 0.03%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
GSKH -It ranks #4 in the industry
Based on market cap of $96B.
GSK $96B PER 15.2
LLY $1.1T PER 38.2
JNJ $642B PER 30.9
ABBV $451B PER 72.1
FAQ
What kind of company is GSK?
GSK belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of GSK?
The market cap of GSK is approximately $96.4B, ranking 174 within its sector.
Does GSK pay dividends?
GSK has a dividend yield of approximately 3.89%, with an annual dividend of $1.87.
What is the P/E ratio of GSK?
GSK has a P/E ratio of approximately 15.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for GSK?
GSK has recorded a 52-week high of $61.69 and a low of $39.29.
